CD33 and acute myeloid leukemia: The construction of another BiKE construct, which acts through CD16 while also targeting the myeloid differentiation antigen CD33, could induce the degranulation and lytic ability of NK cells towards acute myeloid leukemia (AML) cells in vitro [15,70].